Givaudan unwraps post-procedure recovery active

Designed as a skin healing accelerator, PrimalHyal 300 strengthens the skin’s natural defence system and helps accelerate recovery when the barrier is compromised, particularly in post-procedure care.

With aesthetic treatments having increased fivefold over the last 30 years, understanding and supporting this mechanism has never been more critical.

Recent scientific discoveries have highlighted bleomycin hydrolase as a key enzyme involved in hydration, wound healing and epidermal barrier integrity.

PrimalHyal 300 activates skin renewal by boosting bleomycin hydrolase levels by 79%, helping the skin remain hydrated while accelerating its natural recovery.

In ex vivo explant models, even after harsh chemical peeling, PrimalHyal 300 helped restore skin barrier strength in just a few days and significantly increased ceramide content (up to 15-fold versus control) — the natural ‘cement’ that binds skin cells together.

These effects were confirmed by clinical studies conducted on women who underwent deep fractional CO₂ laser treatments.

After three days, there was visible improvement in hydration; after one week, there was substantial reduction in redness and irritation.

Developed in the Champagne region of France through sustainable innovation, PrimalHyal 300 is produced in a biorefinery rooted in the principles of the circular economy, reflecting Givaudan Active Beauty’s commitment to responsible innovation and performance-driven skin science.

“Our skin is our first line of defence — a complex and dynamic structure that must repair itself effectively when compromised,” said Amandine Scandolera, Head of Biological Evaluation at Givaudan Active Beauty.

“PrimalHyal 300 is the result of years of research into how hyaluronic acid can support the skin’s natural repair and cell reconnection processes,” she added.

“By specifically reactivating bleomycin hydrolase production, it helps the skin heal better, faster and more effectively.”